Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.155
No. of companies carrying out R&D in Biotechnology;250 or more employees;145
No. of companies carrying out R&D in Biotechnology;Total 2021;1.299
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;29,7
%Companies according to biotechnology used: Genetic code;250 or more employees;39,5
%Companies according to biotechnology used: Genetic code;Total 2021;30,8
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;37,4
%Companies according to biotechnology used: Functional units;250 or more employees;46,5
%Companies according to biotechnology used: Functional units;Total 2021;38,4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;20,1
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;33,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2021;21,5
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;49,2
%Companies according to biotechnology used: Bioprocesses;250 or more employees;63,2
%Companies according to biotechnology used: Bioprocesses;Total 2021;50,8
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;7,5
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;15,9
%Companies according to biotechnology used: Sub-cellular organisms;Total 2021;8,5
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;23,7
%Companies according to biotechnology used: Bio-computing;250 or more employees;26,4
%Companies according to biotechnology used: Bio-computing;Total 2021;24
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;12,2
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;11,1
%Companies according to biotechnology used: Nanobiotechnology;Total 2021;12,1
%Companies according to biotechnology used: Other;Fewer than 250 employees;17,2
%Companies according to biotechnology used: Other;250 or more employees;14,6
%Companies according to biotechnology used: Other;Total 2021;16,9
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;544
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;15
Companies in which biotechnology activities are: Main and/or exclusive;Total 2021;559
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;191
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;39
Companies in which biotechnology activities are: A secondary line of business;Total 2021;230
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;420
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;90
Companies in which biotechnology activities are: A tool necessary for production;Total 2021;510
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45,9
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;42,3
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total 2021;45,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;15,9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;12,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2021;15,5
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;31,9
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;35,5
%Company by field(s) of ultimate application of biotechnology use: Food products;Total 2021;32,3
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;24,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;20,8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2021;23,8
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;16
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;12,5
%Company by field(s) of ultimate application of biotechnology use: Environment;Total 2021;15,6
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13,9
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;12,5
%Company by field(s) of ultimate application of biotechnology use: Industry;Total 2021;13,7
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;9.560
Personnel in R&D in biotechnology (no. of persons);250 or more employees;6.190
Personnel in R&D in biotechnology (no. of persons);Total 2021;15.750
Personnel in R&D in biotechnology (no. of persons): Research personnel;Fewer than 250 employees;5.506
Personnel in R&D in biotechnology (no. of persons): Research personnel;250 or more employees;2.874
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total 2021;8.379
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Fewer than 250 employees;4.055
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;250 or more employees;3.316
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total 2021;7.371
Personnel in R&D in biotechnology (no. of persons). Women;Fewer than 250 employees;4.963
Personnel in R&D in biotechnology (no. of persons). Women;250 or more employees;3.748
Personnel in R&D in biotechnology (no. of persons). Women;Total 2021;8.711
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Fewer than 250 employees;2.838
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;250 or more employees;1.673
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total 2021;4.510
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Fewer than 250 employees;2.125
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;250 or more employees;2.075
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total 2021;4.200
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;6.711
Personnel in R&D in biotechnology (FTE);250 or more employees;4.817,6
Personnel in R&D in biotechnology (FTE);Total 2021;11.528,6
Personnel in R&D in biotechnology (FTE): Research personnel;Fewer than 250 employees;4.162,2
Personnel in R&D in biotechnology (FTE): Research personnel;250 or more employees;2.180,5
Personnel in R&D in biotechnology (FTE): Research personnel;Total 2021;6.342,7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Fewer than 250 employees;2.548,8
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;250 or more employees;2.637,1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total 2021;5.185,9
Personnel in R&D in biotechnology (FTE). Women;Fewer than 250 employees;3.575,2
Personnel in R&D in biotechnology (FTE). Women;250 or more employees;2.964,6
Personnel in R&D in biotechnology (FTE). Women;Total 2021;6.539,7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Fewer than 250 employees;2.167,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;250 or more employees;1.288,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total 2021;3.455,7
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Fewer than 250 employees;1.407,8
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;250 or more employees;1.676,2
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total 2021;3.084
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;593.445
Internal expenditure on R&D (thousands of euros);250 or more employees;445.137
Internal expenditure on R&D (thousands of euros);Total 2021;1.038.582
1) By nature of the expense: Current expenses;Fewer than 250 employees;531.987
1) By nature of the expense: Current expenses;250 or more employees;408.103
1) By nature of the expense: Current expenses;Total 2021;940.091
1.1) Remuneration to research personnel;Fewer than 250 employees;194.798
1.1) Remuneration to research personnel;250 or more employees;126.772
1.1) Remuneration to research personnel;Total 2021;321.570
1.2) Remuneration to technical and auxiliary personnel;Fewer than 250 employees;91.565
1.2) Remuneration to technical and auxiliary personnel;250 or more employees;103.271
1.2) Remuneration to technical and auxiliary personnel;Total 2021;194.836
1.3) Other current expenses;Fewer than 250 employees;245.624
1.3) Other current expenses;250 or more employees;178.061
1.3) Other current expenses;Total 2021;423.685
2) By nature of the expense: Capital expenses;Fewer than 250 employees;61.458
2) By nature of the expense: Capital expenses;250 or more employees;37.033
2) By nature of the expense: Capital expenses;Total 2021;98.492
2.1) Land and buildings;Fewer than 250 employees;7.788
2.1) Land and buildings;250 or more employees;2.411
2.1) Land and buildings;Total 2021;10.199
2.2) Equipment and instruments;Fewer than 250 employees;40.235
2.2) Equipment and instruments;250 or more employees;32.349
2.2) Equipment and instruments;Total 2021;72.584
2.3) Acquisition of specific R&D software;Fewer than 250 employees;3.600
2.3) Acquisition of specific R&D software;250 or more employees;2.121
2.3) Acquisition of specific R&D software;Total 2021;5.721
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;9.835
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;152
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2021;9.987
1.1) By origin of the funds: Own funds;Fewer than 250 employees;403.266
1.1) By origin of the funds: Own funds;250 or more employees;308.222
1.1) By origin of the funds: Own funds;Total 2021;711.488
1.2) By origin of the funds: From companies;Fewer than 250 employees;75.949
1.2) By origin of the funds: From companies;250 or more employees;45.789
1.2) By origin of the funds: From companies;Total 2021;121.738
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;76.924
1.3) By origin of the funds: Public Administration funds;250 or more employees;30.552
1.3) By origin of the funds: Public Administration funds;Total 2021;107.477
1.4) By origin of the funds: From Universities;Fewer than 250 employees;192
1.4) By origin of the funds: From Universities;250 or more employees;0
1.4) By origin of the funds: From Universities;Total 2021;192
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;1.543
1.5) By origin of the funds: From non profit private institutions;250 or more employees;9.213
1.5) By origin of the funds: From non profit private institutions;Total 2021;10.756
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;35.570
1.6) By origin of the funds: Foreign funds;250 or more employees;51.360
1.6) By origin of the funds: Foreign funds;Total 2021;86.931
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;75.599
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;69.958
Purchase of R&D services in biotechnology (thousands of euros);Total 2021;145.557
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;53.934
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;41.981
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total 2021;95.915
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;21.665
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;27.977
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total 2021;49.642
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;42,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;23,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2021;40,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;13,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;13,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2021;13,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;19,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2021;19
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;15,3
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2021;11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;10,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2021;15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17,8
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;10,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total 2021;17
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;19,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2021;16,4
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;41,2
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;34,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2021;40,5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;56,1
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;46,5
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2021;55
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;22,3
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;18,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2021;21,9
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;24,2
% Companies with income of an international origin related to biotechnological activities;250 or more employees;18,1
% Companies with income of an international origin related to biotechnological activities;Total 2021;23,5
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;10,6
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,8
% Turnover representing income of an international origin related to biotechnological activities;Total 2021;1,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;56
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;69,8
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total 2021;61,6
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;44
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;30,2
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total 2021;38,4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;93,8
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;78,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total 2021;87,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;4,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;19,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total 2021;10,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;0,6
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;1,8
% Income of an international origin related with activities according to the classification: Operating source abroad;Total 2021;1,1
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;0,6
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0
% Income of an international origin related with activities according to the classification: Other;Total 2021;0,4